Works matching IS 2160763X AND DT 2025 AND VI 14 AND IP 6

Results: 9

Clinical Evaluation of Potential Interaction Between Bemnifosbuvir and Ruzasvir With an Assessment of Food Effect: Results of a Phase 1 Study in Healthy Participants.

Published in:

Clinical Pharmacology in Drug Development, 2025, v. 14, n. 6, p. 461, doi. 10.1002/cpdd.1540

By:

Zhou, Xiao‐Jian;
Morelli, Gaetano;
Montrond, Maureen;
Lynch, Shannan;
Pietropaolo, Keith;
Belanger, Bruce;
Horga, Arantxa;
Hammond, Janet

Publication type:

Article

A Phase 1 Study to Evaluate the Pharmacokinetics and Safety of TPN171 (a PDE5 Inhibitor) in Adults with Renal Impairment.

Published in:

Clinical Pharmacology in Drug Development, 2025, v. 14, n. 6, p. 479, doi. 10.1002/cpdd.1536

By:

Fu, Ping;
Song, Yi;
Hu, Chao;
Yong, Xiaolan;
Yu, Yang;
Chen, Yi;
Wang, Ying;
Zhu, Xiaohong;
Wang, Zhen;
Wang, Yu;
Juan, Jiaxiang;
Chen, Yuan;
Miao, Jia

Publication type:

Article

Pharmacokinetics and Safety of TPN171 (a PDE5 Inhibitor) in Patients With Mild or Moderate Hepatic Impairment Versus Participants With Normal Hepatic Function: A Phase 1 Study.

Published in:

Clinical Pharmacology in Drug Development, 2025, v. 14, n. 6, p. 472, doi. 10.1002/cpdd.1535

By:

Zhou, Jing;
Zhang, Hong;
Ding, Yanhua;
Wang, Zhen;
Wang, Yu;
Juan, Jiaxiang;
Jiang, Zhicheng;
Chen, Hong

Publication type:

Article

A Phase 1C, Open Label, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of DM199 Administered Intravenously with a Polyvinyl Chloride Bag in Adult Healthy Subjects and Adults Recently Taking Angiotensin‐Converting Enzyme Inhibitors

Published in:

Clinical Pharmacology in Drug Development, 2025, v. 14, n. 6, p. 452, doi. 10.1002/cpdd.1534

By:

Giuffre, Michael;
Lista, Annette D.;
Paulson, Nick;
Masuoka, Lorianne

Publication type:

Article

Pharmacokinetics and Safety of a Fixed‐Dose Combination of Alogliptin and Extended‐Release Metformin Under Fasting and/or Fed Conditions in Healthy Adults.

Published in:

Clinical Pharmacology in Drug Development, 2025, v. 14, n. 6, p. 443, doi. 10.1002/cpdd.1532

By:

Song, Ji Hye;
Kim, Jae Hoon;
Hong, Jang Hee;
Jung, Jin‐Gyu;
Park, Sun Young;
Sunwoo, Jung

Publication type:

Article

Extrapolation of Midazolam Disposition in Neonates Using Physiological‐Based Pharmacokinetic/Pharmacodynamic Modeling.

Published in:

Clinical Pharmacology in Drug Development, 2025, v. 14, n. 6, p. 415, doi. 10.1002/cpdd.1531

By:

Zhao, Tangping;
Lv, Zhanhui;
Zhou, Sufeng;
Wang, Lu;
Li, Tongtong;
Zhu, Jinying;
Shao, Feng

Publication type:

Article

Bioequivalence and Tolerability of 2 Lurasidone Formulations: A Randomized, Single‐Dose, 2‐Period, Crossover Study in Healthy Chinese Subjects Under Fasting and Fed Conditions.

Published in:

Clinical Pharmacology in Drug Development, 2025, v. 14, n. 6, p. 436, doi. 10.1002/cpdd.1529

By:

Yu, Hengyi;
Fang, Yinian;
Qi, Xingxing;
Luo, Pan;
He, Zheng;
Wang, Kaifu;
Lei, Yongfang;
Zhang, Donglin;
Zuo, Qin;
Liu, Chang;
Chen, Qian;
Liu, Dong;
Ren, Xiuhua

Publication type:

Article

Comparative Bioequivalence Study of 2 Fixed‐Dose Combinations of Vildagliptin and Metformin at a Tablet Strength of 50/1000 mg in Moroccan Volunteers.

Published in:

Clinical Pharmacology in Drug Development, 2025, v. 14, n. 6, p. 428, doi. 10.1002/cpdd.1528

By:

Lazrak, Salma;
Ouaouda, Oumaima;
Bektachi, Jalal;
Iraqi, Mohamed Ali;
El Khabbaz, Choukri;
Cherrah, Yahya

Publication type:

Article

Issue Information.

Published in:: Clinical Pharmacology in Drug Development, 2025, v. 14, n. 6, p. 411, doi. 10.1002/cpdd.1283
Publication type:: Article